Leading animal healthcare company,
Hester Biosciences Ltd reported a standalone net profit of Rs8.86cr for the Quarter ended March 2021 as against net profit of Rs5cr in the corresponding period last year – growth of 77%.
Net sales for the Q4FY21 was reported at Rs63.16cr, growth of 52% as compared to net sales of Rs41.43cr in the corresponding period last year.
EPS for Q4FY21 was reported at Rs10.41 per share.
The company is able to maintain healthy margins; EBITDA Margin was reported at 32.62% and Net Profit margin at 14.03% in Q4FY21.
The Board of directors has recommended a dividend of Rs10 per equity share (100%) for FY21, subject to the approval of the shareholders.
This dividend recommendation is in line with the company’s dividend policy to distribute a minimum of 18% of the PAT.
Business Overview of Hester India for FY21
-
The year FY21 has been in line with the financial forecasts and the budgets. During FY21, the overall topline grew by 23% compared to the topline of FY20.
-
Domestic sales have registered a growth of 55% in Q4FY21 and 29% in FY21. There was a steep rise in local demand, mainly for the poultry vaccines and health products. Bird-flu incidences in the poultry led towards heavy usage of preventive and curative medication which led an increase in the demand.
-
Export sales have registered a marginal growth of 3% in Q4FY21 and a marginal degrowth of 4% in FY21. The main reason for the exports remaining flat in the year was a more or less stand-still in airlines cargo movement due to covid
-
While quarter to quarter gross margins have always been oscillating within a band, the overall year’s EBIDTA margins have improved.